Infusion Reactions With Antibody Therapy — What Happens on the First Dose

Not most cancer patients. Antibody therapy works only where the biopsy shows the surface marker the antibody is built to attach to. In practice that means a defined group of B-cell blood cancers. Eligibility is read off the histopathology and immunohistochemistry report. It is not decided by the word “immunotherapy”.

That matters before anything else on this page, because families often arrive having read about a treatment that was never on the table for their diagnosis. If the marker is not there, the antibody has nothing to bind to, and no amount of asking will change that. A haemato-oncologist reads the report and says which class of treatment applies.

Where it does apply, the idea is simple. The antibody is given into a vein. It attaches to a marker on the surface of the cancer cell and flags that cell for your immune system to clear. It is usually given alongside a chemotherapy backbone rather than on its own, and NCCN and ESMO have placed it in first-line care for the common B-cell subtypes for more than two decades.

This is a different treatment from checkpoint immunotherapy, which does not touch the cancer cell at all — it releases a brake on your own T cells. Both get called immunotherapy in conversation. Their side-effect patterns are not alike. Antibody therapy’s defining early risk is an infusion reaction, concentrated in the first dose, which is what the rest of this page is about.

Nothing on this page decides eligibility, and no medicine is named on it. What applies to you depends on the subtype, the stage, previous treatment and overall fitness, read together by a haemato-oncologist.

Because the first dose meets the most target cells. When large numbers of those cells are cleared quickly, inflammatory chemicals are released into the blood, and that release is what most first-dose reactions are made of. Running the infusion slowly spreads it over hours instead of minutes.

There is a second reason, and it is just as important. A slow start means that if a reaction does begin, it begins when very little of the dose has gone in. The team can pause, treat it, and still have the option of finishing the infusion later that day. A fast infusion removes that margin.

In practice the rate is stepped. The first thirty minutes run at a low rate. If your temperature, pulse, blood pressure and oxygen readings stay stable, the rate is increased a step at a time, with a fresh set of observations after each increase. A first infusion commonly takes several hours from start to finish, and the day is planned around that rather than squeezed.

Later cycles are usually quicker. Once a first dose has been given without a significant reaction, the risk falls sharply, and many plans move to a shorter infusion from the second cycle onwards. If the first dose is long and the second is half the length, that is the protocol working, not a change in your treatment.

Stepped infusion rates with premedication before the first dose are described as standard practice in guidance from bodies including NCCN and ESMO. The exact schedule differs between plans, so ask your day-care nurse for the one written for you.

Chills and shivering with a fever are the commonest pattern. Most reactions begin within thirty minutes to two hours of starting the first dose, often just after the rate has been stepped up. Most are mild to moderate and settle once the infusion is paused and treated. A small number are severe and are managed as an emergency in the unit.

Timing above is the general pattern described in published guidance, not a fixed rule. Reactions can start earlier, later, or on a cycle that has always gone smoothly. Nothing here is home-management advice: during an infusion the correct response is always to tell the nurse, and at home it is to call the helpline or go to the emergency department.

By medicines given before the infusion and a rate that starts low. Premedication goes in roughly thirty to sixty minutes ahead. Baseline observations are recorded. The infusion then begins slowly and is stepped up only while you stay stable, with a nurse present throughout. Prevention is planned in advance, not improvised on the day.

• Antibody and chemotherapy infusions — given at CION as day care at our centres, with premedication, stepped infusion rates and observation throughout. You come in, are watched during and after the infusion, and go home the same day. An overnight stay is not part of a routine cycle.
• A reaction on the day — managed in the unit. The infusion is paused, the symptoms are treated, and the decision to restart, slow down or stop is made by the treating team on the spot. Emergency medicines and equipment are kept in the day-care area for exactly this reason.
• Tumour board and written second opinion — given at CION. Medical, surgical and radiation oncologists review the case together. The diagnosis, the plan and the reasoning are explained before the first cycle, not afterwards.
• CAR-T cell therapy and stem cell transplant — not provided at CION. CION Cancer Clinics does not administer, stock or manufacture CAR-T or any other cell therapy, and does not perform stem cell transplant. Both are referred to designated centres licensed and equipped for them, and we will say so plainly where that is the right next step.
• Response-assessment PET-CT — coordinated, not owned. Scans are arranged at partner imaging centres and reported back into the plan. Costs are discussed openly before treatment begins, any figure quoted is indicative, as of August 2026, and no price is attached to a named product — see Cost of Blood Cancer Immunotherapy in India.

The first infusion feels like the whole event when it is a week away. It is worth remembering that it is one day in a longer plan, and that the questions with the shortest deadline are not always the ones about the infusion itself. Fertility, long-term monitoring and cost all have decisions attached to them that are easier to make before cycle one than after it.

• For patients in their twenties and thirties, Immunotherapy for Lymphoma in Young Adults: Late Effects covers long-term monitoring, what is followed up for years afterwards, and where the evidence is still genuinely immature.
• If money is the pressure sitting behind the medical decision, Cost of Blood Cancer Immunotherapy in India explains what drives the figure and how scheme and insurance cover is worked out.
• Anything with a deadline before cycle one belongs in the first conversation — Fertility Preservation Before Blood Cancer Immunotherapy is the clearest example.
• For how immune-based treatment is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Still unsure what the first infusion will involve for a specific diagnosis? Book a free consultation and a medical oncologist will go through the reports and the plan with you.